MedTrace Logo

Zalutumumab in Patients With Non-curable Head and Neck Cancer

NCT00382031 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 286

Last updated 2013-10-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate if zalutumumab in combination with Best Supportive Care (BSC) is superior to BSC in non-curable patients with head and neck cancer

Conditions

Interventions

DRUG

Zalutumumab

Individual dose titration weekly i.v doses

OTHER

Control

Best Supportive Care

Sponsors & Collaborators

  • Genmab

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2009-12-31
Completion
2011-08-31

Countries

  • Belgium
  • Brazil
  • Canada
  • Estonia
  • France
  • Hungary
  • Lithuania
  • Poland
  • Russia
  • Serbia
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00382031 on ClinicalTrials.gov